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Abstract
Weaning is associated with a major shift in the microbial community of the intestine, and this instability may make it more acquiescent than
the adult microbiota to long-term changes. Modulation achieved through dietary interventions may have potentially beneficial effects on
the developing immune system, which is driven primarily by the microbiota. The specific aim of the present study was to determine
whether immune development could be modified by dietary supplementation with the human probiotic Bifidobacterium lactis
NCC2818 in a tractable model of weaning in infants. Piglets were reared by their mothers before being weaned onto a solid diet
supplemented with B. lactis NCC2818, while sibling controls did not receive supplementation. Probiotic supplementation resulted in
a reduction in IgA (P,0·0005) and IgM (P,0·009) production by mucosal tissues but had no effect on IgG production (P.0·05). Probio-
tic-supplemented pigs had more mast cells than unsupplemented littermates (P,0·0001), although numbers in both groups were low. In
addition, the supplemented piglets made stronger serum IgG responses to fed and injected antigens (P,0·05). The present findings are
consistent with B. lactis NCC2818 reducing intestinal permeability induced by weaning, and suggest that the piglet is a valuable
intermediate between rodent models and human infants. The results also strongly suggest that measures of the effect of probiotic sup-
plementation on the immune system need to be interpreted carefully as proxy measures of health benefit. However, they are useful in
developing an understanding of the mechanism of action of probiotic strains, an important factor in predicting favourable health outcomes
of nutritional intervention.
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It is clear that the intestinal microbiota provides the first line
of defence against pathogenic organisms(1,2). However, it is
becoming more apparent that it also exerts a major influence
over host homeostasis in healthy humans and animals(3–6).
The microbiota can be altered by factors such as diet(7) and
environment(4–6), but in adults, the mature microbiota tends
to re-establish itself once the external influence is removed(8).
More long-term alterations may be generated during early life,
when this intestinal ecosystem is still fluctuating(9) and highly
susceptible to change(10,11). The process of microbial colonisa-
tion and succession in the intestine is a major factor in driving
maturation of the immune system(12–16), and the composition
of the microbiota can affect the function of the immune
system in neonates and adults(17). Some specific modifications
of the microbiota have been correlated with disease(10,18,19),
and clinical trials have suggested that strain-specific probiotic
therapy can confer a health benefit for specific disease situ-
ations(20–24). The process of weaning is associated with a
major shift in the gut microbial community in both humans(25)
and other mammals(26), and therefore may present a target for
beneficial manipulation of the microbiota. Intervention with
probiotics during weaning may have a more pronounced
impact on the subsequent function of the immune system
than administration of probiotics to adults.
Assessing the likely value of a probiotic in a specific clinical
situation requires either direct measurement of health benefit
as part of a clinical trial, or an understanding of the mechanism
of action of the probiotic. The size and robustness of the
evidence base will allow rational selection of specific pro-
biotic strains and the clinical situations in which trials are
*Corresponding author: Dr M. C. Lewis, fax þ44 1179 289 505, email marie.lewis@bristol.ac.uk
Abbreviations: MLN, mesenteric lymph node; PP, Peyer’s patches.
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likely to have positive outcomes. However, the extent to which
mechanistic studies can be carried out in human subjects is
limited. Neonates of altricial species such as rodents are not
easily manipulated: in contrast, the omnivorous pig is not
only similar to humans in terms of anatomical, physiological,
immune and metabolic characteristics(27–31) but, in addition,
their precocial development makes them appropriate candi-
dates for manipulation around weaning.
Effects of early-life environment on microbial colonisation
have been identified in young piglets(4), and intra-individual
stability and inter-individual variability of the microbiota are
more similar between humans and pigs than between humans
and mice(32). Further, full genome studies have demonstrated
less differences between humans and pigs than between
humans and rodents(33,34). These factors suggest that piglets
are a valuable intermediate between highly reductionist,
mechanistic studies in mice, and human epidemiological
studies and clinical trials, especially with regard to weaning
and nutritional intervention. Here we use a healthy piglet wean-
ing model to identify the effects of intervention with the human
probiotic Bifidobacterium lactis at weaning on immunological
development and function, and question how well generally
accepted proxy measures of health truly reflect the physiologi-
cal status of an individual.
Materials and methods
Animals
Animal housing and experimental procedures were all
performed according to local ethical guidelines: all experi-
ments were performed under a UK Home Office License
and were approved by the local ethical review group. A
total of seven outbred sows were artificially inseminated
using semen from a single boar (supplied by Hermitage-Sea-
borough Limited). Sows were transported to the Department
of Clinical Veterinary Science 6 weeks before parturition and
fed on a wheat-based diet (BOCM Pauls Limited). At 3 weeks
of age, piglets were weaned and litter-matched into six groups
(Table 1), each group being housed in a separate room, on
straw, in standard large animal facilities.
At this point, three groups received the B. animalis subsp.
lactis (CNCM I-3446) probiotic diet supplementation in the
form of spray-dried culture mixed into the formula at a concen-
tration of 4·2 £ 106 colony-forming units/ml (approximately
2 £ 109 colony-forming units/kg metabolic weight per d). The
required quantity of feed supplemented with fresh probiotics
was fed twice per d to the appropriate groups (A–C) until the
experiment concluded when the pigs were 11 weeks old. The
remaining groups (D–E) did not receive the probiotic sup-
plement. The probiotic-fed and control animals were in differ-
ent suites separated by a biosecurity barrier. Of the piglets
receiving probiotics, two groups were weaned onto a soya-
based diet and one onto an egg-based diet (Table 2). All diets
were supplemented with appropriate levels of vitamins and
minerals and were manufactured to order by Volac (Parnutt)
Foods Limited. The weaning diets were designed such that
the only differences were that each contained 21 % of the
stated protein. One of the two groups that weaned onto the
soya-based diet also received an intraperitoneal injection of
2 mg soluble ovalbumin from chicken egg-white (systemic
exposure; Sigma) and 2 mg Quil A adjuvant (Brenntag Biosector
A/S) in 2 ml PBS to investigate the immune response against a
systemically administered novel protein. The treatment of
these three probiotic-supplemented groups (A–C) was repli-
cated in the probiotic-free control groups D to F. From
7 weeks of age, all six groups were fed a fishmeal-based diet,
free of egg and soya, either with or without probiotic as appro-
priate. The fishmeal diet was used to ensure that the serum anti-
body response was to the injected egg protein and not to the
dietary egg protein. The egg- and soya-based diets were
designed to meet the nutritional requirements of piglets
between 3 and 7 weeks old, whereas the fishmeal-based diet
was designed for piglets between 7 and 11 weeks old. For this
reason, the fishmeal-based diet cannot be compared with the
egg- and soya-based diets. The composition of the different
diets is shown in Table 2. At 9 weeks old, all piglets received
an intraperitoneal injection of 2 mg ovalbumin and 2 mg Quil
A adjuvant in 2 ml PBS.
All piglets were bled by venepuncture at 3, 4, 5, 7 and
9 weeks old for collection of serum. At 11 weeks old, piglets
Table 1. Experimental design*
Group (n 7 per group)
Age (weeks) Treatment A B C D E F
3 Weaning diet Egg Soya Soya Egg Soya Soya
Bifidobacterium lactis NCC2818 þ þ þ 2 2 2
Inject i.p. 2 OVA 2 2 OVA 2
Bleed þ þ þ þ þ þ
4 Bleeds þ þ þ þ þ þ
5 Bleed þ þ þ þ þ þ
7 Bleed þ þ þ þ þ þ
Fishmeal diet þ þ þ þ þ þ
9 Bleed þ þ þ þ þ þ
Inject i.p. OVA OVA OVA OVA OVA OVA
11 Killing þ þ þ þ þ þ
i.p., Intraperitoneally; OVA, ovalbumin.
* Forty-two (six piglets from seven litters) piglets were litter-matched into six treatment groups; three groups received the B. lactis NCC2818 intervention at
weaning at 3 weeks of age.
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were sedated with azaperone and killed with an overdose of
barbiturate. At post-mortem, heart blood and tissues were
recovered.
Tissue culture
At killing, 4 cm2 samples of intestinal mucosa (proximal and
distal jejunum, excluding Peyer’s patches (PP), distinct jejunal
PP, caecum and descending colon), and 1 cm3 of spleen and
mesenteric lymph node (MLN) were collected and placed in
cold sterile medium. Organ fragment culture was carried out
as described in detail by Logan et al.(35). Briefly, the samples
were vigorously washed three times in Ca2þ and Mg2þ-free
Dulbecco’s PBS (Sigma) containing 0·5 mM-EDTA (Sigma),
1 M-HEPES (Invitrogen) and 50mg gentamycin/ml (Gibco),
followed by three further washes in Ca2þ and Mg2þ-free
Dulbecco’s PBS containing 1% HEPES and 50mg gentamycin/ml
before being placed in Roswell Park Memorial Institute-
1640 medium (Sigma) containing 10 % fetal calf serum
(PAA), 200 mM-L-glutamine (Invitrogen), 10 units penicillin/ml
and 10mg streptomycin/ml (Invitrogen) and 50mg gentamy-
cin/ml (complete medium). Intestinal tissues were cut into frag-
ments approximately 3 mm2, while spleen and MLN were cut
into 2 mm cubes, and one fragment of tissue was placed in
each of six individual wells of a twenty-four-well culture plate
(Corning, Inc.) containing 1 ml of complete medium. Cultures
were incubated at 378C, 5 % CO2, 100 % humidity for 96 h,
after which they were frozen at 2208C. The plates were
defrosted and the spent medium from each of the six duplicate
wells for each sample was pooled and refrozen for analysis of Ig
content.
Immunoglobulin assays
Catching ELISA was carried out to determine total IgG1, IgG2,
IgA and IgM in spent medium from organ fragment cultures
and IgA in serum. Briefly, ninety-six well microplates were
coated with either affinity-purified goat anti-pig IgG (H þ L),
goat anti-pig IgA or goat anti-pig IgM (Bethyl Laboratories).
Serial dilutions of serum samples and reference standard were
added to coated plates and incubated for 2 h at room tempera-
ture. Bound Ig were detected using isotype-specific monoclonal
antibodies (anti-pig IgA K61.1B4, anti-pig IgM K52.1C3, anti-pig
IgG1 K139.3C8 and anti-pig IgG2 K68.1G2; all from Serotec) fol-
lowed by horseradish peroxidase-conjugated goat anti-mouse
IgG1. Concentrations of Ig subclasses were determined by
interpolation of samples onto the reference standards.
Antigen-specific immunoglobulin assays
Serum samples were analysed for anti-ovalbumin IgG1 and IgG2
antibodies by ELISA as described in detail by Bailey et al.(36).
Briefly, ninety-six-well microplates were coated with oval-
bumin from chicken egg-white (Sigma) before non-specific
binding sites were blocked with 2 % bovine serum albumin
(Sigma) in PBS–Tween 20. After washing, serial dilutions
of serum samples and reference standard were added to
the plates. Reference standard was porcine serum obtained
Table 2. Composition of the weaning diets and supplements
Ingredients (%) Egg-based Soya-based Fishmeal-based
Whole dried egg 24·3 2 2
Extruded full-fat soya (unmodified, 35 %
protein, 19 % fat)
2 17·6 2
High-protein soya (48 % protein, 2·7 % fat) 2 12·2 2
LT94 Fishmeal 2 2 12·5
Wheat 2 2 30·0
Full-fat whey (50 % lard) 2 2 3·5
Potato protein (Roquette) 2 2 2·5
Barley 2 2 10·0
Cooked wheat (MASHM) 21·0 19·4 16·7
Presco maize 21·0 19·7 10·0
Cooked naked oats 11·7 9·2 2
Dairy crest tint whey 9·4 8·8 5·0
Denatured skimmed milk-A 7·7 6·7 5·0
Dextrose 1·7 1·6 1·5
Vitamin and mineral mix* 1·0 1·0 1·0
SNOWCAL chalk 10 2 2 0·6
Dicalcium phosphate 0·9 1·5 0·3
Limestone Trical 130 0·5 0·5 0·5
L-Lys 0·4 0·4 0·3
L-Thr 0·1 0·1 0·1
Salt 0·1 0·1 0·1
Protein 21·3 21·2 21·5
Oil 12·5 11·2 7·1
Fibre 1·1 2·3 1·7
Ash 4·5 5·3 5·1
Moisture 8·6 9·9 10·8
N-free extract 52·0 50·1 53·8
* Vitamin and mineral mix (calculated units in finished feed): vitamin A, 16 mg/kg; vitamin D3, 2 mg/kg; vitamin E, 250 mg/kg; vitamin K (menadione),
4 mg/kg; vitamin B1, 10 mg/kg; vitamin B2, 16 mg/kg; vitamin B6, 10 mg/kg; vitamin B12, 0·05 mg/kg; nicotinic acid, 50 mg/kg; pantothenic acid,
30 mg/kg; biotin (vitamin K), 0·2 mg/kg; vitamin C, 200 mg/kg; folic acid, 3 mg/kg; choline chloride, 300 mg/kg. Trace minerals: Cu, 155 mg/kg; Fe,
375 mg/kg; Zn, 110 mg/kg, Mn, 100 mg/kg; Co, 0·5 mg/kg; I, 1·2 mg/kg; Se, 0·3 mg/kg.
Supplementation at weaning affects immunity 1245
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following hyperimmunisation with ovalbumin. Bound
anti-soya IgG1 and IgG2 antibodies were detected using
isotype-specific monoclonal antibodies followed by HRP-
conjugated goat anti-mouse as mentioned previously, and
relative concentrations of antibody were determined by
interpolation of samples onto the reference standards.
In order to compare changes in serum antibody generated
by weaning and by the injection of novel proteins in outbred
animals, in which the starting levels differ, results are
expressed as the ratio of antibody after manipulation to that
before manipulation (fold change in antibody).
Immunohistology
Sample collection. MLN and caecum tissue was removed
shortly after death from each of the experimental piglets. Tissues
were embedded in OCT (Tissue TEK; BDH), snap-frozen in iso-
pentane and pre-cooled to approximately2708C in the vapour
phase of liquid N2. Samples were stored at2808C until section-
ing. Serial 5mm sections of these tissues were cut using a Model
OTF cryotome (Bright Instrument Company Limited). Sections
were air-dried for 24 h and then fixed by immersion in acetone
for 15 min. Slides were allowed to dry before storage at2808C.
Fluorescence immunohistology. For two-colour fluor-
escence immunohistology, mouse anti-pig monoclonal anti-
bodies (IgA and IgM, as for ELISA) were used to identify free
and cell-bound IgA- and IgM-positive cells and B-lymphocytes
(anti-CD21, clone IAH CC55). The conjugated secondary
reagents used were as follows: goat anti-mouse IgG1 conjugated
to fluorescein isothiocyanate (FITC) (Southern Biotechnology,
AMS Biotechnology) and goat anti-mouse IgG2b conjugated to
tetramethyl rhodamine isothiocyanate (TRITC) (Southern Bio-
technology). Tissue staining, image capture and automated
image analyses were carried out as described by Inman
et al. (37) with the exception that fracture crystallography (Fc)
receptor blocking was achieved using 10 % goat serum in PBS.
Histochemistry
Small-intestinal samples were obtained as described in the
immunohistology section and processed the same up to and
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Fig. 1. Total (a, b) IgA and (c, d) IgM production (mg/ml, log-transformed) by organ fragment cultures from organised (a, c) lymphoid tissues and (b, d) non-
lymphoid tissues from piglets supplemented with Bifidobacterium lactis NCC2818 (groups A, B and C) or unsupplemented (groups D, E and F). Values are
means, with their standard errors represented by vertical bars (n 21). a,b Mean value with unlike letters was significantly different from that of probiotic supplemen-
tation (P,0·01; t test with Bonferroni correction). MLN, mesenteric lymph node; JPP, jejunal Peyer’s patches; Pro SI, proximal small intestine; Dis SI, distal small
intestine. B, B. lactis; A, control.
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including the acetone fixation step. Fixed slides were stained
for mast cells using 2·5 % toluidine blue O solution (Sigma-
Aldrich) for 15 s followed by dehydration through increasing
concentrations of alcohol culminating in a histoclearw
(National Diagnostics) wash and mounted in distyrene plasti-
ciser xytene (DPX) mounting medium (Fisher). Image capture
was carried out using a Colour Coolview camera and Image-
Pro Plus software (Photonic Science). Thereafter, ten fields
of view were obtained from each piglet and ImageJ software
(National Institutes of Health) was used to allow quantification
of mast cells per cm2 tissue.
Statistical analysis
Statistical analysis was carried out using SPSS statistics (SPSS,
Inc.). Univariate linear regression was carried out using piglet
as the experimental unit and litter, tissue and probiotic treat-
ment as variables. Individual differences between the treatment
groups were determined by least significant differences as in
our previous experiments(3).
Results
Local immunoglobulins
Bifidobacterium lactis NCC2818 supplementation caused a
reduction in local immunoglobulin production in lymphoid-
associated organ fragment cultures. Total IgG1, IgG2, IgA
and IgM were quantified in organ fragment culture medium
from all animals. There were highly significant differences in
the amounts of the four isotypes produced between tissues
(P,0·0001), spleen producing less IgA (20·16 (SEM 0·04) log10
mg/ml) than mucosal tissues in the control animals (mean
range20·5–1·16 log10 mg/ml). Highly significant effects of pro-
biotic intervention were observed for IgA (P,0·0005; Fig. 1(a)
and (b)) and IgM (P,0·009; Fig. 1(c) and (d)), but not for
IgG1 or IgG2 (data not shown). IgA and IgM were lower in the
probiotic supplemented animals than in the unsupplemented
animals (for IgA from MLN, 20·56 (SEM 0·09) and 0·34 (SEM
0·05) log10 mg/ml, respectively; from proximal jejunum, 0·75
(SEM 0·03) and 0·86 (SEM 0·01) log10 mg/ml; from jejunal PP,
0·02 (SEM 0·09) and 0·80 (SEM 0·09) log10 mg/ml; from caecum,
0·74 (SEM 0·06) and 1·17 (SEM 0·05) log10 mg/ml; for IgM from
MLN, 0·38 (SEM 0·08) and 0·72 (SEM 0·03) log10 mg/ml, respect-
ively; from caecum, 0·13 (SEM 0·18) and 0·85 (SEM 0·03) log10
mg/ml; from colon, 0·60 (SEM 0·04) and 0·81 (SEM 0·03)) log10
mg/ml). There was also a significant interaction between pro-
biotic treatment and tissue (P,0·0001 for both classes), such
that this effect was more marked for some tissues than others.
Specifically, probiotic intervention appeared to have the most
marked effect on IgA production by the organised tissues of
MLN and jejunal PP (Fig. 1(a)), and to a lesser extent by the dif-
fuse lymphoid tissue present in caecal mucosa (Fig. 1(b)).
Although supplementation also resulted in significantly
decreased IgA production by tissue from the proximal small
intestine, the effect was much smaller. IgA production in the
spleen, distal small intestine and colon showed no difference
between the probiotic supplemented and non-supplemented
animals (from spleen, 20·25 (SEM 0·04) and 20·16 (SEM
0·04) log10 mg/ml, respectively; from distal jejunum, 0·46 (SEM
0·03) and 0·44 (SEM 0·07) log10 mg/ml; from colon, 1·16 (SEM
0·02) and 1·06 (SEM 0·05) log10 mg/ml). There was also no differ-
ence as a result of dietary supplementation in spleen or small-
intestinal IgM (for spleen, 0·62 (SEM 0·09) and 20·79 (SEM
0·06) log10 mg/ml, respectively; from proximal jejunum, 0·36
(SEM 0·07) and 0·36 (SEM 0·07) log10 mg/ml; for distal jejunum,
0·27 (SEM 0·06) and 0·40 (SEM 0·05) log10 mg/ml; for discrete jeju-
nal PP, 0·75 (SEM 0·05) and 0·35 (SEM 0·05) log10mg/ml). It should
be noted that IgA in serum taken at time points throughout the
experiment remained unaltered by the supplementation with B.
lactis NCC2818 (P.0·05).
Local IgA and IgM proteins were reduced in caecal tissue,
mesenteric lymph node-associated B-cells and B-cell follicles
following probiotic intervention. In order to examine the
mechanisms by which probiotic administration reduced Ig
secretion in organ fragment cultures, levels of IgA, IgM and
CD21 were examined in MLN (Figs. 2 and 3) and caecum
(Fig. 4) samples from groups B and E (soya diet, supplemented
with the probiotic and control, respectively). These tissues and
groups were chosen as they had previously produced the most
consistent differences in organ fragment cultures. Consistent
with the organ fragment culture data, there was reduced
expression of IgA (Fig. 2(a) and (d)), IgM (Fig. 2(d)) and also
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Fig. 2. Fluorescence immunohistology of the mesenteric lymph node from
treatment groups B (ovalbumin priming and recall and Bifidobacterium lactis
NCC2818 intervention; B) and E (ovalbumin priming and recall without
B. lactis NCC2818 intervention; A). (a) Example field from treatment group
B: green fluorescence indicates binding of anti-pig IgA monoclonal antibody
and red, anti-pig CD21 monoclonal antibody. (b) Example field from treat-
ment group E stained similarly. (c) Proportional area of expression of CD21
and (d) IgA and IgM in the same treatment groups (group B, B. lactis
NCC2818; group E, control). Values are means, with their standard errors
represented by vertical bars (n 7). *** Mean value was significantly different
from that of group B (P,0·0001 in all cases). (A colour version of this figure
can be found online at http://www.journals.cambridge.org/bjn)
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CD21 (Fig. 2(c)), within B-cell follicles in the MLN of the B. lactis
NCC2818-treated animals compared with the control group
(P,0·0001). There was no effect of intervention with B. lactis
NCC2818 on the total number of MLN follicles (P.0·05;
Fig. 3(a)), but the number of IgM-specific follicles (Fig. 3(c))
and extrafollicular IgM-producing B-cells (Fig. 3(b)) was
reduced in the animals receiving the intervention (P,0·0001).
In contrast, no change was seen in the number of extrafollicular
IgA-positive cells (Fig. 3(b), P.0·05), whereas the number of
IgA-specific follicles was actually significantly increased
(Fig. 3(c)) in animals fed with B. lactis NCC2818 when com-
pared with the controls (P,0·0001). Reductions in the
expression of IgA (Fig. 4(a) and (c)) and IgM (Fig. 4(b) and
(d)) in situ in the caecum were also apparent (Fig. 4), both in
the subepithelial lamina propria (associated with production)
and in the caecal crypt epithelium (associated with transport)
(Fig. 4(c) and (d)).
A reduction in lymphoid-associated IgA and IgM
production was associated with increased mast cell
numbers in the intestinal mucosa
In contrast to the decreases observed in IgA and IgM in the
supplemented animals, there were significantly greater num-
bers of mast cells in the small intestine (P,0·001) of animals
which received B. lactis NCC2818 (n 7) when compared
with the control (Fig. 5).
Systemic antibody
Primary systemic response to novel fed protein at weaning
was increased following Bifidobacterium lactis NCC2818
administration. At weaning, there was a significant increase
in IgG2 anti-soya antibody in animals which received a soya
diet with probiotic supplementation when compared with
both the animals fed soya without probiotic and the egg-fed
animals (P¼0·021; Fig. 6(a)). The supplemented animals also
mounted a significantly greater IgG1 antibody response to
soya compared with the egg-fed controls (P¼0·03), and a
greater response than the unsupplemented animals fed soya,
although this was not significant (Fig. 6(b)).
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Fig. 4. Fluorescence immunohistology of caecum crypts and lamina propria
from soya-fed piglets which received intraperitoneal ovalbumin priming and
recall (treatment groups B and E) and either (a) Bifidobacterium lactis
NCC2818 supplementation or (b) not; fluorescence indicates the binding of
anti-pig IgA monoclonal antibody. (c) IgA and (d) IgM fluorescence quantified
(P,0·0001 in all cases). Values are means, with their standard errors rep-
resented by vertical bars (n 7). B, B. lactis; A, control. (A colour version of
this figure can be found online at http://www.journals.cambridge.org/bjn)
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Fig. 3. B-cell follicles in the mesenteric lymph node from soya-fed piglets that received intraperitoneal ovalbumin priming and recall and Bifidobacterium lactis
NCC2818 intervention (treatment group B; B) or no B. lactis NCC2818 intervention (treatment group E; A), identified by fluorescence immunohistology. (a) Total
number of follicles present in tissues: no significant difference between the animals receiving the B. lactis NCC2818 intervention and those that did not. (b) Extra-
follicular cells containing either IgA or IgM. (c) Number of IgA- or IgM-positive follicles. Values are means, with their standard errors represented by vertical bars
(n 7). *** Mean value was significantly different from that of the control group (P,0·0001).
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Primary and secondary responses to injected antigens
were increased following probiotic intervention at weaning.
Fig. 7(a) and (b) shows the increase in serum IgG1 and IgG2 anti-
body, respectively, during the primary and secondary responses
to systemically injected antigens (with the adjuvant). During the
primary response (3–5 weeks old), there were trends towards
an increased serum IgG1 and IgG2 anti-ovalbumin response in
the B. lactis NCC2818-fed animals (n 7) compared with the con-
trol group. During the secondary response (9–11 weeks old),
there was a significantly greater response in both isotypes in
the supplemented group (IgG1, P¼0·05 and IgG2, P¼0·02).
Discussion
The common definition of a probiotic (given by the WHO
in 2001) is ‘a live microorganism that when administered in
adequate amounts confers a health benefit on the host’. Thus,
the definitive outcome measure necessary when testing novel
strains for probiotic activity is health: in normal or diseased
humans or animals, this may be measured, for example,
by susceptibility to disease. However, understanding the
mechanisms by which probiotics function requires detailed
measurement of a wider range of immunological and physio-
logical parameters, which may then also be used as proxy
measures of health. The strain of B. lactis NCC2818 used in
the present experiments has been identified as having probiotic
activity, as defined above, in human subjects and in rodent
models. These benefits include reducing pathogen load and
prevention or reduction of antibiotic-associated diarrhoea(38,39).
However, the effects of probiotics, including B. lactis NCC2818,
on immune development at weaning, a time when the resident
microbiota is changing rapidly, are largely unknown. The
immunological measures reported here, then, relate to the
mechanisms of action of the probiotic strain and to the iden-
tification of proxy measures of the probiotic effect. The results
presented clearly demonstrate that administration of B. lactis
to piglets at weaning had marked effects on the structure and
function of the mucosal immune system. In that respect, the
present results are comparable with mechanistic experiments
in rodents and with the data from human clinical trials.
In our system, intervention with B. lactis NCC2818 resulted
in reduced IgA in mucosal-associated lymphoid tissues
(associated with a reduction in plasma cell numbers by immu-
nohistology). In contrast, preterm infants, which received
B. lactis NCC2818 for 3 weeks following birth, showed a
2-fold increase in faecal IgA levels from 2 weeks onwards(40),
and IgA production by MLN and PP cells from adult mice was
increased when cultured in the presence of Bifidobacterium
bifidum (41). In a mouse study, IgA in the intestinal fluids of
the supplemented animals was also higher than that in the
controls. In these and previous studies, elevated secretory
IgA has been presumed to be a mechanism or a proxy
measure for a beneficial effect of probiotics(42), presumably
by increasing the potential for neutralisation of allergens or
pathogen, thus preventing or reducing disease. The disparity
between the present results and those reported in human sub-
jects and rodents may be more apparent than real. Where
intervention has resulted in increased IgA levels in vivo, it
should be noted that faecal IgA levels and total intestinal
washes, as normally carried out in these species, may be
more reflective of jejunal and/or colonic mucosal IgA levels,
where there was no effect of supplementation in pigs of the
present study, rather than the MLN, PP and caecum, where
there was an effect. In addition, studies in human subjects
have frequently involved compromised individuals(40),
–0·5
–0·4
–0·3
–0·2
–0·1
0·0
0·1
0·2
0·3
0·4
Lo
g
10
 n
u
m
b
er
 o
f 
m
as
t 
ce
lls
B. lactis Control
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from piglets (n 7) weaned onto a soya diet and given intraperitoneal oval-
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whereas the present study used normal, outbred healthy pig-
lets. While an increase in faecal IgA has been correlated with
protection, the same correlation has not been established for
local tissue IgA. Interestingly, an increase in intestinal IgA
can be linked to various disease states in humans(43–45), and
a local increase of IgA in a healthy individual can also be an
indication of the loss of barrier function. We thus suggest
that the present observation that probiotic supplementation
decreased, rather than increased, local IgA production in intes-
tinal tissue reflects a reinforcement of the intestinal barrier
(preventing exposure to luminal antigens) rather than a sup-
pression of mucosal immunity, and a breakdown in barrier
function is often associated with disease. It also suggests that
while elevated IgA in the faeces is accepted as a proxy
measure for health, the same interpretation cannot necessarily
be applied to local IgA production in tissues.
Similarly, although elevated numbers of mast cells have
been associated with allergic sensitisation(46), the increases
in mast cell numbers seen here were within the normal
ranges previously reported in young piglets(47,48), and are in
line with physiological numbers in adult pigs(49) and were
not comparable with those seen in disease states(50,51). An
increase in mast cell numbers within the normal physiological
range may be a consequence of increased recruitment to the
intestinal mucosa, decreased mast cell exit or the inhibition
of mast cell degranulation. Previous studies have suggested
that mast cell degranulation contributes to impaired barrier
function after weaning in young piglets, and several
probiotic species have been shown to reduce IgE-mediated
degranulation in an RBL-2H3 cell line(39,51). A reduction in
antigen-induced mast cell degranulation may also occur as a
consequence of elevated IgG antibody responses to fed and
injected antigens in probiotic supplemented animals: elevated
serum IgG antibody responses to food proteins have been
associated with decreased susceptibility to IgE-mediated aller-
gic disease in human subjects and to post-weaning diarrhoea
in pigs(52,53). Further, since active, primary responses to
intestinal antigens are largely mediated through PP(54) while
tolerance is mediated by the transfer of antigens from the
intestinal mucosa to the MLN(55), stronger responses to fed
antigens in supplemented piglets may also indicate reduced
uptake across the intestinal epithelium compared with PP.
The present results strongly suggest caution in interpreting
specific measures of the immune system (in this case, IgA pro-
duction, mast cell numbers and antibody to food proteins) as
linear, proxy measures for the health benefit of probiotic sup-
plementation in the diet without taking the specific animal
model and, more importantly, the specific intervention
window into account.
Mechanistically, the present results are largely consistent
with B. lactis NCC2818 intervention, increasing barrier func-
tion between the lumen and the intestinal lamina propria.
Specifically, a reduction in IgA production in organ fragment
cultures is entirely consistent with a reduced exposure of the
mucosal immune system to antigens derived from the intesti-
nal lumen. Previously, certain probiotics, including bifidobac-
teria, have been shown to enhance the barrier function of
human intestinal epithelial cells in vitro (56), but not in vivo,
in part by the stabilisation of tight cell junctions(57).
B. bifidum, for example, was demonstrated to increase barrier
integrity in a rat model of neonatal necrotising enterocolitis(58).
In conclusion, the present results demonstrate clear effects
of probiotic supplementation in the weaning diets of conven-
tionally reared animals which do not have any diseases or
unusual pathology. Mechanistically, these effects are consist-
ent with increased barrier function. However, the results also
strongly suggest that while measures of the effect of probiotic
supplementation on the immune system are of value in devel-
oping an understanding of the mechanism of action, we may
need to interpret with caution. While studies of health benefits
are appropriately conducted in human subjects, mechanistic
studies require tractable animal models from which sufficient
tissue samples can be easily recovered. Such mechanistic
studies should, perhaps, be carried out in several mammalian
species in order to establish generally applicable principles for
predicting the activities of probiotic strains.
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